Singapore Paincare
Sias calls on Singapore Paincare to clarify actions after failed privatisation bid
Move is in light of the impact the collapsed deal has on minority shareholders
Singapore Paincare privatisation bid fails as offeror fails to meet conditions by deadline
The counter will resume trading on Dec 8
Singapore Paincare settles dispute over claims worth S$350,000 to S$450,000
It did not disclose the amount of the settlement
Singapore Paincare receives letters of claim worth S$350,000 to S$450,000
Its CEO has indemnified the company for the claimed sums
Sias raps Singapore Paincare for WhatsApp pressure on shareholders over privatisation offer
It says such communication is a breach of takeover code
IFAs should hew to thinking of the market
Excessively discounting plainly visible value within a target company, and making spurious comparisons, may erode confidence in their independence and objectivity
Singapore Paincare up 12.1% as Sias urges shareholders to await IFA report
The activist for good corporate governance and investor rights says the company could be worth up to S$0.37 a share, more than twice its S$0.16 offer price
Sias calls for Singapore Paincare shareholders to await IFA opinion on privatisation offer
It notes that the group could be worth more as ‘well-managed healthcare companies generally trade at premiums to their net asset value’
The privatisation offer for this small Catalist company could cause SGX some discomfort
The proposal to take Singapore Paincare private comes a mere five years after IPO, and highlights the local bourse’s chronic lack of liquidity
Singapore Paincare receives privatisation offer at S$0.16 per share
It is agreeing to the proposed acquisition to give its shareholders an opportunity to exit their investment at a premium
